Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial
Open Access
- 1 August 2021
- journal article
- research article
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 14, 1045-1063
Abstract
Background: Subcutaneous immunotherapy (SCIT) has been proven as an effective therapy against some allergens for seasonal allergic rhinitis (SAR) patients unresponsive to intranasal corticosteroids and/or antihistamines but carries risk of systemic allergic reactions. Dupilumab blocks the shared receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflammation in multiple diseases. Objective: To evaluate the efficacy and safety of SCIT+dupilumab vs SCIT alone. Methods: This phase 2a, multicenter, double-blind, placebo-controlled parallel-group study conducted in 103 adults with grass pollen-induced SAR (NCT03558997) randomized patients 1:1:1:1 to SCIT, dupilumab (300 mg every 2 weeks), SCIT+dupilumab, or placebo. SCIT was administered using an 8-week cluster protocol followed by 8 weeks of maintenance injections. Primary endpoint was change from pre-treatment baseline in area under the curve (AUC) in total nasal symptom score (TNSS) 0– 1 h following nasal allergen challenge (NAC) with timothy grass extract at Week 17. Results: Although 16 weeks of treatment with SCIT+dupilumab did not significantly improve TNSS AUC (0– 1 h) following NAC at Week 17 vs SCIT (least squares mean − 56.76% vs − 52.03%), a higher proportion of SCIT+dupilumab-treated patients (61.5%) achieved SCIT maintenance dose vs SCIT (46.2%). A lower proportion of SCIT+dupilumab-treated patients (7.7%) required epinephrine rescue treatment vs SCIT (19.2%). There were significantly fewer withdrawals in the SCIT+dupilumab group than in the SCIT group (n = 2 [7.7%] vs n = 8 [30.8%]; P = 0.0216); the majority of SCIT group withdrawals were due to SCIT-related intolerability, compared with no discontinuations from the SCIT+dupilumab group. Conclusion: In SAR patients, 16 weeks of SCIT+dupilumab may improve SCIT tolerability but did not incrementally reduce post-allergen challenge nasal symptoms compared with SCIT alone. Clinical Study Number: NCT03558997.Keywords
This publication has 44 references indexed in Scilit:
- Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapyAllergy, 2011
- Systemic reactions with aeroallergen cluster immunotherapy in a clinical practiceAnnals of Allergy, Asthma & Immunology, 2011
- Allergen immunotherapy: A practice parameter third updateJournal of Allergy and Clinical Immunology, 2011
- Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading SystemJournal of Allergy and Clinical Immunology, 2010
- Side‐effects of allergen‐specific immunotherapy. A prospective multi‐centre studyClinical & Experimental Allergy, 2006
- Evaluation of near-fatal reactions to allergen immunotherapy injectionsJournal of Allergy and Clinical Immunology, 2006
- Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLARAllergy, 2004
- Long-Term Clinical Efficacy of Grass-Pollen ImmunotherapyNew England Journal of Medicine, 1999
- Interleukin 4 causes isotype switching to IgE in T cell-stimulated clonal B cell cultures.Journal of Experimental Medicine, 1988
- Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: A six-year prospective studyJournal of Allergy and Clinical Immunology, 1982